Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Open access

Abstract

AIMS: The effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish whether statins reduce major HF events. METHODS AND RESULTS: We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized controlled endpoint statin trials from 1994 to 2014. Collaborating trialists provided unpublished data from adverse event reports. We included primary- and secondary-prevention statin trials with >1000 participants followed for >1 year. Outcomes consisted of first non-fatal HF hospitalization, HF death and a composite of first non-fatal HF hospitalization or HF death. HF events occurring <30 days after within-trial myocardial infarction (MI) were excluded. We calculated risk ratios (RR) with fixed-effects meta-analyses. In up to 17 trials with 132 538 participants conducted over 4.3 [weighted standard deviation (SD) 1.4] years, statin therapy reduced LDL-cholesterol by 0.97 mmol/L (weighted SD 0.38 mmol/L). Statins reduced the numbers of patients experiencing non-fatal HF hospitalization (1344/66 238 vs. 1498/66 330; RR 0.90, 95% confidence interval, CI 0.84-0.97) and the composite HF outcome (1234/57 734 vs. 1344/57 836; RR 0.92, 95% CI 0.85-0.99) but not HF death (213/57 734 vs. 220/57 836; RR 0.97, 95% CI 0.80-1.17). The effect of statins on first non-fatal HF hospitalization was similar whether this was preceded by MI (RR 0.87, 95% CI 0.68-1.11) or not (RR 0.91, 95% CI 0.84-0.98). CONCLUSION: In primary- and secondary-prevention trials, statins modestly reduced the risks of non-fatal HF hospitalization and a composite of non-fatal HF hospitalization and HF death with no demonstrable difference in risk reduction between those who suffered an MI or not.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv072

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of literature search to identify randomized placebo-controlled trials, standard care-controlled trials, and dose-comparison statin trials.
Figure 1 Flow diagram of literature search to identify randomized placebo-controlled trials, standard care-controlled trials, and dose-comparison statin trials.CC BY · PubMed Central
Image 2
CC BY · PubMed Central
Figure 2 The effect of statin therapy on the risk of (A) first non-fatal heart failure hospitalization in 17 trials (B) heart failure death in 14 trials (C) first composite heart failure outcome in 14 trials. All heart failure events within 30 days of myocardial infarction were excluded.
Figure 2 The effect of statin therapy on the risk of (A) first non-fatal heart failure hospitalization in 17 trials (B) heart failure death in 14 trials (C) first composite heart failure outcome in 14 trials. All heart failure events within 30 days of myocardial infarction were excluded.CC BY · PubMed Central
Figure 3 Funnel plot for non-fatal heart failure hospitalization. Egger test P = 0.74.
Figure 3 Funnel plot for non-fatal heart failure hospitalization. Egger test P = 0.74.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 163

Metadata

Authors
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., Amarenco, P., Pedersen, T. R., Tikkanen, M. J., Koren, M. J., Poulter, N. R., Sever, P. S., Ridker, P. M., MacFadyen, J. G., Solomon, S. D., Davis, B. R., Simpson, L. M., Nakamura, H., Mizuno, K., Marfisi, R. M., Marchioli, R., Tognoni, G., Athyros, V. G., Ray, K. K., Gotto, A. M., Clearfield, M. B., Downs, J. R., & McMurray, J. J.
Affiliations
  • University of Glasgow (GB)
  • Western Infirmary (GB)
  • The George Institute for Global Health (GB)
  • University of Dundee (GB)
  • University of California, San Francisco (US)
  • SUNY Downstate Health Sciences University (US)
  • Hôpital Bichat-Claude-Bernard (FR)
  • Oslo University Hospital (NO)
  • University of Helsinki (FI)
  • Jacksonville Center for Clinical Research (US)
  • Imperial College London (GB)
  • Brigham and Women's Hospital (US)
  • Mitsukoshi Health and Welfare Foundation (JP)
  • Nippon Medical School (JP)
  • Mario Negri Sud Foundation (IT)
  • Aristotle University of Thessaloniki (GR)
  • Weill Cornell Medicine (US)
  • Touro University California (US)
  • The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Preiss, David
Venue
European Heart Journal
Published
2015-03-23
Volume
36
Issue
24
Pages
1536-1546
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2104553590
Cited by
160
References
51
Citations by year
2026: 10 · 2025: 14 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 13 · 2020: 9 · 2019: 17 · 2018: 19 · 2017: 12 · 2016: 14 · 2015: 10
FWCI
3.51
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • European Heart Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Research Bank (Australian Catholic University) (submittedVersion, cc-by)
  • Touro Scholar (Touro College) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Pfizer
  • National Institute for Health and Care Research (CDF-2013-06-012, NF-SI-0513-10059)
  • British Heart Foundation (PG/13/17/30050)
  • University of Glasgow
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
statins, heart failure, heart failure hospitalization, heart failure mortality, LDL cholesterol lowering, primary prevention, secondary prevention, myocardial infarction, cardiovascular risk reduction, statin safety
MeSH terms
Female, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehv072
The paper
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., Amarenco, P., Pedersen, T. R., Tikkanen, M. J., Koren, M. J., Poulter, N. R., Sever, P. S., Ridker, P. M., MacFadyen, J. G., Solomon, S. D., . . . McMurray, J. J. (2015). The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.